News & Updates

Mindfulness programme may benefit COVID survivors

17 Jun 2025 by

A mindfulness-based stress reduction (MBSR) programme may improve functional and psychosocial outcomes in patients with long COVID, a study suggests.

Mindfulness programme may benefit COVID survivors

17 Jun 2025

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

17 Jun 2025

Treatment with the investigational oral orexin receptor 2–selective agonist oveporexton appears to yield improvements in wakefulness, sleepiness, and cataplexy in individuals with narcolepsy type 1, according to the results of a phase II study.

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

17 Jun 2025

Risk factors for late-onset epilepsy among people with cognitive decline identified

16 Jun 2025

Factors such as APOE4 allele, dementia onset before age 60 years, Alzheimer’s disease (AD) dementia subtype, worse cognition, stroke/transient ischaemic attack (TIA), and Parkinson’s disease (PD) all contribute to a heightened risk of late-onset epilepsy in people with cognitive decline, as reported in a study.

Risk factors for late-onset epilepsy among people with cognitive decline identified

16 Jun 2025

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025 by

Fremanezumab appears to provide a two-for-one benefit in patients with migraine and comorbid depressive disorder, with data from the UNITE study showing that the drug helped reduce migraine days and lift mood.

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025 by

Treatment with SGLT2 inhibitors can prolong the life of patients with amyloidosis with or without a diagnosis of heart failure (HF), a study has shown.

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025

Vitamin D protective against BPPV

16 Jun 2025 by

A group of researchers from Changi General Hospital in Singapore found lower rates of benign paroxysmal positional vertigo (BPPV) recurrence among older adults who supplemented their diet and Canalith Repositioning Procedure (CRP) with vitamin D.

Vitamin D protective against BPPV

16 Jun 2025

Preconception C. trachomatis seropositivity may up risk of miscarriage

16 Jun 2025

Among women with a history of pregnancy loss, prior exposure to Chlamydia trachomatis poses an increased risk of miscarriage, as reported in a study.

Preconception C. trachomatis seropositivity may up risk of miscarriage

16 Jun 2025

Real-World Evidence in Action: Integrating data into the management of MDR Gram-negative infections

16 Jun 2025

A Pfizer-sponsored symposium held during ESCMID 2025 in Vienna, Austria explored the expanding role of real-world evidence (RWE) in managing multidrug-resistant (MDR) Gram-negative bacterial infections. The session featured three distinguished experts, Professor David van Duin from the University of North Carolina, US; Dr Paula Ramirez, an intensive care specialist at La Fe University and Polytechnic Hospital, Spain; and Professor David Paterson from the National University of Singapore, who is also the Director of ADVANCE-ID, a regional platform for infectious disease research. Together, they discussed how RWE complements traditional clinical trials, guides empirical treatment strategies, and supports the use of newer antibiotics such as ceftazidime-avibactam.

Real-World Evidence in Action: Integrating data into the management of MDR Gram-negative infections

16 Jun 2025

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

15 Jun 2025 by

Treatment with targeted-release budesonide formulation preserves kidney function and reduces proteinuria in patients with IgA nephropathy (IgAN) independent of baseline eGFR, and this benefit is seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period, according to a subanalysis of the phase III NeflgArd study presented at the ERA annual meeting.

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

15 Jun 2025

Probiotic supplement may improve cognition, mood in older adults

15 Jun 2025

Supplementation with probiotics appears to induce an acute effect on reaction times during executive function, hinting at the possibility of preventing the development of depression among older adults, according to a study.

Probiotic supplement may improve cognition, mood in older adults

15 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Mindfulness programme may benefit COVID survivors

Mindfulness programme may benefit COVID survivors

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

Risk factors for late-onset epilepsy among people with cognitive decline identified

Risk factors for late-onset epilepsy among people with cognitive decline identified

Fremanezumab tackles migraine, depression at the same time

Fremanezumab tackles migraine, depression at the same time

SGLT2i extends survival in amyloidosis patients with or without HF

SGLT2i extends survival in amyloidosis patients with or without HF

Vitamin D protective against BPPV

Vitamin D protective against BPPV

Preconception C. trachomatis seropositivity may up risk of miscarriage

Preconception C. trachomatis seropositivity may up risk of miscarriage

Real-World Evidence in Action: Integrating data into the management of MDR Gram-negative infections

Real-World Evidence in Action: Integrating data into the management of MDR Gram-negative infections

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

Probiotic supplement may improve cognition, mood in older adults

Probiotic supplement may improve cognition, mood in older adults